Insulin - Tujeo Solostar

Pharmacodynamics
Babban mahimmancin aikin insulin, gami da insulin glargine, shine reflux na metabolism. Insulin da analogues din sa suna rage tarowar glucose a cikin jini, yana karfafa shaye shaye ta hanyar kyallen tsinkaye (musamman kasusuwa da tsohuwar nama) da kuma hana samuwar glucose a cikin hanta. Insulin yana hana lipolysis a cikin adipocytes (ƙwayoyin mai) kuma yana hana proteinolysis, yayin da yake haɓakar aikin furotin.
Halayen Magunguna
Insulin glargine kwatanci ne na insulin ɗan adam wanda aka samu ta sake haɗawa da DNA na ƙwayoyin halittar ɗan adam Escherichia coli (K12 damuwa) ana amfani dashi azaman mai samarwa. Yana da ƙananan solubility a cikin tsaka tsaki yanayi. A pH 4 (a cikin yankin acidic), glargine insulin gabaɗaya yana narkewa. Bayan gabatarwar cikin kitse na subcutaneous, tasirin acidic na mafita yana magance, wanda ke haifar da samuwar microprecipitate, daga abin da ake ƙyamar ƙananan ƙwayar insulin glargine a koyaushe.
An fara aiki da allurar insulin glygine allurai 100ED / ml a hankali idan aka kwatanta da insulin na isofan dan adam, yanayin aikin sa yayi kyau kuma ba tare da kololuwa ba, kuma tsawan sa ya tsawaita (bayanai daga binciken kararrawar kwayoyi da aka gudanar cikin masu sa kai da marasa lafiya da masu fama da sukari nau'in ciwon sukari 1).
Tasirin hypoglycemic na shirye-shiryen Tujeo SoloStar® bayan aikinta na subcutaneous, idan aka kwatanta da wannan tare da subcutaneous management na insulin glargine 100 IU / ml, ya kasance mafi yawan yanayi a cikin girma kuma ya tsawanta (bayanai daga bincike na tsaka-tsallake-euglycemic-36 a cikin awa 18 da aka gudanar tare da sukari nau'in ciwon sukari 1). Ayyukan miyagun ƙwayoyi Tujeo SoloStar® sun dauki sama da awanni 24 (har zuwa awanni 36) tare da tsarinta na subcutaneous a cikin magunguna masu mahimmanci (duba adadi da ke ƙasa).

Tsawancin hypoglycemic na Tujeo SoloStar®, yana ɗaukar sama da awanni 24, yana ba da damar, idan ya cancanta, canza lokacin sarrafa maganin a cikin sa'o'i 3 kafin ko 3 sa'o'i bayan lokacin allurar da ta saba wa mara lafiya (duba sashin "Hanyar gudanarwa da sashi").
Bambanci a cikin hanyoyi na tasirin hypoglycemic na Tujeo SoloStar® da insulin glargine 100 IU / ml suna da alaƙa da canji a cikin sakin insulin glargin daga hazo.
Don adadin adadin rakalan insulin glargine, ɗaukar nauyin Tujeo SoloStar® shiri shine kashi ɗaya bisa uku na lokacin da ake sarrafa insulin glargine 100 IU / ml. Wannan yana haifar da raguwa a cikin yanki na hazo, wanda ke ba da ƙarin sakin insulin glargine mafi hankali daga haɓakar shirye-shiryen Tujeo SoloStar®, idan aka kwatanta da insulin na glargine 100 IU / ml.
Lokacin da aka ba da allurai insulin glargine da insulin na mutum a cikin jijiya, tasirin tasirinsu ya kasance iri ɗaya.
Sadarwa tare da masu karɓar insulin: insulin glargine yana metabolized zuwa metabolites biyu masu aiki, Ml da M2 (duba sashin Pharmacokinetics). Bincike a cikin vitro ya nuna cewa kusancin insulin glargine da metabolites dinsa Ml da M2 ga masu karbar insulin na mutum suna kama da na insulin na mutum.
Sadarwa tare da insulin-kamar girma factor 1 masu karɓa (IGF-1):
kusancin insulin glargine ga mai karɓar IGF-1 kusan sau 5-8 ne sama da na insulin ɗan adam (amma kusan sau 70-80 da ƙasa da na IFR-1), yayin da ake kwatanta insulin metabolites da insulin ɗan adam. glargine Ml da M2 suna da kusancin kusanci don mai karɓar IGF-1 idan aka kwatanta da insulin ɗan adam. Jimlar warkewar insulin (maida hankali ne kan ƙarancin insulin glargine da kuma metabolites), an ƙaddara a cikin marasa lafiya da nau'in ciwon sukari na 1 na ƙananan ƙwayar cuta, ya kasance mafi ƙanƙanci fiye da maida hankali da ake buƙata na rabin-iyakar dauri ga masu karɓar IGF-1 da kuma kunnawa na mitogenic proliferative wayway jawo ta hanyar masu karɓar IGF-1 . Rationsarfafawar ilimin halittar jiki na IGF-1 yana iya kunna hanyar haɓakawa na mitogenic, kodayake, abubuwan kwantar da hankali na insulin da aka ƙaddara a yayin aikin insulin, ciki har da magani tare da Tujeo SoloStar®, suna da ƙasa sosai fiye da maida hankali kan magungunan da ake buƙata don kunna hanyar mitogenic proliferative way.
Sakamakon da aka samu a duk gwaji na asibiti na Tujeo SoloStar® wanda aka gudanar tare da jimlar marasa lafiya 546 da ke da nau'in ciwon sukari na 1 da masu haƙuri 2474 da ke da nau'in ciwon 2 ya nuna raguwa a cikin ƙwayar haemoglobin (HbAlc) idan aka kwatanta da ƙimarsu ta farko. dabi'u, a ƙarshen karatun ba su da ƙasa da wannan a cikin jiyya tare da insulin glargine 100 IU / ml.
Adadin marasa lafiya da suka kai darajar darajar HbAlc (a ƙasa da 7%) ya yi daidai a cikin rukunin jiyya biyu.
Rage yawan haɗarin glucose na plasma a ƙarshen binciken tare da Tujeo SoloStar® da insulin glargine 100 IU / ml iri ɗaya ne, amma a lokaci guda, tare da kulawa tare da Tujeo SoloStar®, wannan raguwa ya kasance mafi hankali yayin lokacin zaɓi.
A cikin marasa lafiyar da aka kula da su tare da Tujeo SoloStar®, a ƙarshen lokacin kulawa na watanni 6, an lura da karuwar nauyin ƙasa da 1 kg.
Haɓaka HbAlc ya kasance mai zaman kansa daga jinsi, ƙabila, shekaru, tsawon lokacin ciwon sukari mellitus, HbAlc, ko ƙididdigar jiki (BMI) a sakamakon.
A cikin marasa lafiya da ke fama da nau'in ciwon sukari na 2 na sukari, sakamakon binciken na asibiti ya nuna ƙananan ciwo mai tsanani da / ko tabbatar da hypoglycemia, kamar yadda aka tsara hypoglycemia tare da alamun asibiti, lokacin da aka kula da Tujeo SoloStar®, idan aka kwatanta da insulin glargine 100 U / ml.
Amfani da Tujeo SoloStar® akan insulin glargine 100 IU / ml wajen rage haɗarin haɓaka mai tsanani da / ko tabbatar da rashin lafiyar hyctglycemia da aka tabbatar a cikin marasa lafiya waɗanda a baya sun karɓi magungunan maganin ƙwayoyin cuta na kwayar cuta (raguwar 23% cikin haɗari) ko insulin tare da abinci (raguwa 21% cikin hadarin ) a cikin lokacin daga mako na 9 har zuwa ƙarshen binciken, idan aka kwatanta da magani na glargine insulin tare da 100 PIECES / ml.
A cikin rukuni na marasa lafiya da aka bi da Tujeo SoloStar®, idan aka kwatanta da marasa lafiya da aka kula da su tare da insulin glargine 100 U / ml, an lura da raguwar haɗarin hypoglycemia, duka a cikin marasa lafiyar da suka taɓa karbar maganin insulin kuma a cikin marasa lafiyar da ba su sami insulin a baya ba, raguwa Hadarin ya fi girma a cikin makonni 8 na farko na jiyya (lokacin magani na farko) kuma bai dogara da shekaru ba, jinsi, tsere, ƙididdigar jiki (IM G), da tsawon lokacin ciwon sukari (> shekaru 10).
A cikin marasa lafiya da ke dauke da nau'in 1 na ciwon sukari na mellitus, raunin hypoglycemia yayin kulawa tare da Tujeo SoloStar® ya kasance daidai da wanda a cikin marasa lafiya da aka bi da insulin glargine 100 U / ml. Koyaya, abin da ya faru na rashin lafiyar ƙwaƙwalwar ƙwaƙwalwar ƙwayar cuta (don kowane nau'in hypoglycemia) a lokacin lokacin kulawa na farko ya kasance ƙasa a cikin marasa lafiya da aka bi da Tujeo SoloStar® idan aka kwatanta da marasa lafiya da aka bi da insulin glargine 100 U / ml.
A cikin gwaji na asibiti, gudanarwa guda ɗaya na Tujeo SoloStar® a cikin rana tare da tsayayyen jadawalin gudanarwa (a lokaci guda) ko kuma jadawalin gudanarwa mai sauƙin aiki (aƙalla sau 2 a mako, an gudanar da maganin ne 3 hours kafin ko 3 sa'o'i bayan lokacin al'ada Gudanarwa, sakamakon abin da ya katse tsakanin jinkiri zuwa gwamnatoci zuwa 18 sa'o'i kuma ya tsawan sa'o'i 30) yana da ma'amala iri ɗaya a kan ƙididdigar HbAlc, ƙwaƙwalwar ƙwayar cutar plasma mai ɗorewa (GPC) da matsakaiciyar darajar ƙarshen allurar riga-kafin. matsalar glucose a cikin jini a lokacin yankewar kai. Bugu da ƙari, lokacin amfani da Tujeo SoloStar® tare da jadawalin lokaci ko sassauya, babu bambance-bambance a cikin fargabawar jini a kowane lokaci na rana ko da daddare a cikin dare. Sakamakon binciken da aka kwatanta Tujeo SoloStar® da insulin glargine 100 IU / ml ba su nuna kasancewar kowane bambance-bambance a cikin inganci ba, aminci ko kashi na insulin basal wanda ke da alaƙa da samuwar ƙwayoyin cuta zuwa insulin tsakanin marasa lafiya da aka bi da Tujeo SoloStar® da insulin. Glargine 100 PIECES / ml (duba sashin "Tasirin sakamako").
A cikin kasa da kasa, multicenter, bazuwar binciken, ORIGIN (Sakamakon Sakamakon Sakamakon Ciwon Glargine INtervention), wanda ya shafi marasa lafiya 12,537 da ke fama da cutar glycemia mai rauni (HH), raunin glucose mai rauni (NTG) ko kuma matakin farko na ciwon sukari na 2 da mellitus da kuma tabbatar da cututtukan zuciya, an nuna su. cewa insulin glargine jiyya tare da 100 PIECES / ml, idan aka kwatanta da daidaitaccen ilimin aikin hypoglycemic, bai canza haɗarin ci gaba da rikicewar cututtukan zuciya ba (mutuwar zuciya, infarction myocardial mara nauyi ko rashin mai). hadarin bugun jini, hadarin farfadowa, aikin ciwan zuciya, ci gaban albuminuria ko kuma hadarin kamuwa da asibiti don haɓakar bugun zuciya.Harin haɗarin rikicewar microvascular (haɗuwa mai nuna alamun rikicewar microvascular: laser photocoagulation ko vitrectomy, hangen nesa sakamakon ciwon sikila, ci gaban albuminuria ko kuma yawan yawan kirkirar halitta a cikin jini, ko kuma abin da ya faru na buƙatar yin maganin dialysis).
A cikin binciken da ke nazarin tasirin insulin glargine 100 IU / ml akan ci gaban cututtukan cututtukan ƙwaƙwalwar ƙwaƙwalwar ƙwayar cuta yayin lura shekara biyar na marasa lafiya da ke da nau'in ciwon sukari na 2, babu wani bambance-bambance masu mahimmanci a cikin npoi martani na ciwon sukari yayin kula da insulin glargine 100 IU / ml, idan aka kwatanta da insulin isofan.
Groupsungiyoyin haƙuri na musamman
Jinsi da tsere
Babu bambance-bambance a cikin inganci da amincin Tujeo SoloStar® da insulin glargine 100 IU / ml dangane da jinsi da tseren marasa lafiya.
Tsofaffi marasa lafiya
A cikin gwajin asibiti da aka sarrafa, marasa lafiya 716 (23% na yawan jama'a don ƙididdigar lafiya) tare da nau'in 1 da nau'in ciwon sukari na 2 sun shekara> 65 shekara kuma marasa lafiya 97 (3%) sun shekara> 75. Gaba ɗaya, babu bambance-bambance a cikin inganci da amincin miyagun ƙwayoyi tsakanin waɗannan marasa lafiya da marasa lafiya na ƙarami. A cikin tsofaffi marasa lafiya da ciwon sukari mellitus, don guje wa halayen hypoglycemic, kashi na farko da kashi na tabbatarwa ya kamata ya zama ƙasa, kuma karuwa ya kamata ya zama mai hankali. Tsofaffi marasa lafiya na iya samun wahalar gane rashin farin jini. Ana ba da shawarar kulawa da hankali sosai akan yawan glucose na jini, kuma yakamata a daidaita sashin insulin ɗaiɗaikun (duba ɓangaren "Sashi da Gudanarwa" da "Pharmacokinetics").
Marasa lafiya tare da gazawar koda
A cikin gwaje-gwajen asibiti da aka sarrafa, ƙaddamar da ƙananan ƙididdiga dangane da yanayin aikin kodan (wanda aka ƙaddara a sakamakon ƙimar ƙwaƙwalwar glomerular> 60 ml / min / 1.73 m2 na jikin jikin) bai nuna bambance-bambance ba ga aminci da inganci tsakanin Tujeo SoloStar® da insulin glargine 100 U / ml Ana ba da shawarar kulawa da hankali sosai game da tattarawar glucose na jini, kuma ya kamata a daidaita sashin insulin ɗaiɗaikun (duba "Sashi da Gudanarwa" da "Pharmacokinetics").
Masu cutar Obese
A cikin nazarin asibiti, bincike mai zurfin ƙananan abubuwa dangane da ƙididdigar taro na jiki (BMI) (har zuwa 63 kg / m 2) bai nuna bambance-bambance a cikin inganci da aminci tsakanin Tujeo SoloStar® da insulin glargine 100 IU / ml ba.
Marasa lafiyar yara
Babu bayanai game da amfani da miyagun ƙwayoyi Tujo SoloStar® a cikin yara.
Pharmacokinetics
Orazantawa da rarrabawa
Bayan allurar cututuka na Tujeo SoloStar® ga masu sa kai masu lafiya da marasa lafiya da ke fama da cutar sankara, yawan tarawar insulin yana nuna jinkirin da yalwataccen lokaci, wanda ke haifar da saurin maida hankali-lokaci har zuwa awanni 36, idan aka kwatanta shi da glargine insulin. 100 PIECES / ml. Veaukaka lokaci-lokaci na Tujeo SoloStar® yayi daidai da tsarin aikinta na aikin harhada magunguna. An sami daidaituwa mai daidaituwa a cikin kewayon maida hankali ga warkewa bayan kwanakin 3-4 na yau da kullun amfani da miyagun ƙwayoyi Tujo SoloStar®.
Bayan da allurar subcutaneous na Tujeo SoloStar®, saɓani a cikin wannan haƙuri, wanda aka bayyana a matsayin mai rarrabewa game da bambancin yanayin shigar insulin na tsawon awanni 24 a yanayin isa yaduwa, ya yi ƙasa (17.4%).
Tsarin rayuwa
A cikin mutane, bayan subcutaneous management na Tujeo SoloStar®, insulin glargine yana haɗuwa da hanzari ta hanyar carbonxyl end (C-terminus) na sarkar P don samar da metabolites guda biyu masu aiki Ml (21A-Gly-insulin) da M2 (21 A-Gly-des-30B- Thr-insulin). Mafi yawan metabolite Ml na zagaya cikin jini. Tsarin magungunan Ml metabolite yana ƙaruwa tare da ƙara yawan allurai na Tujeo SoloStar.. Kwatanta magunguna da bayanan magunguna sun nuna cewa maganin yana haifar da tasirin ƙirar Ml metabolite. A cikin mafi yawan masu haƙuri, ba za a iya gano insulin glargine da metabolite M2 ba a cikin kewaya tsarin. A cikin yanayin inda har yanzu yana yiwuwa a gano insulin glargine da metabolite M2 a cikin jini, yawan haɗuwar su bai dogara da kashi da aka gudanar da kuma sashi na insulin glargine ba.
Kiwo
Rabin rayuwar metabolite Ml, mai mahimmanci mai mahimmanci na miyagun ƙwayoyi Tujo SoloStar®, bayan allurar subcutaneous na miyagun ƙwayoyi shine 18-19 hours, ba tare da la'akari da kashi ba.
Ah!takamaiman kungiyoyin haƙuri
Shekaru da jinsi
Babu wani bayani game da tasirin launin fata da jinsi a kan magunguna na insulin glargine (duba sashen Pharmacodynamics).
Tsofaffi marasa lafiya
Ba a yi nazarin sakamakon tsufa kan magunguna na Tujeo SoloStar® ba tukuna. A cikin tsofaffi marasa lafiya da ke fama da ciwon sukari mellitus, don guje wa halayen hypoglycemic, kashi na farko da ƙaddamar da kulawa ya kamata ya zama ƙasa, kuma karuwar kashi ya kamata ya zama mai hankali (duba sassan "Pharmacodynamics" da "Hanyar aikace-aikace da allurai").
Yara
A cikin marasa lafiyar yara, har yanzu ba a yi nazarin magungunan likitancin na Tujeo SoloStar® ba.
Marasa lafiya tare da na koda da hepatic kasawa
Ba a yi nazarin tasirin renal da rashin hepatic a kan magunguna na miyagun ƙwayoyi Tujo SoloStar® ba tukuna. Koyaya, wasu nazarin tare da insulin ɗan adam sun nuna karuwar yawan insulin a cikin marasa lafiya da keɓaɓɓen renal da hepatic insufficiency. Kulawa da hankali sosai game da tattarawar glucose na jini da daidaituwa na daidaituwa na insulin ana bada shawarar (duba sassan "Sashi da Gudanarwa" da "Umarnin na Musamman").

Contraindications

A cikin mata masu juna biyu (yiwuwar canza buƙatar insulin a lokacin daukar ciki da kuma bayan haihuwa), tsofaffi marasa lafiya (dubasassan "Pharmacokinetics", "Pharmacodynamics", "Sashi da Gudanarwa" da "Umarni na Musamman"), marasa lafiya da ke fama da rikice-rikicen endocrine (kamar su hypothyroidism, karancin adenohypophysis da adrenal cortex), tare da cututtukan da ke tattare da amai ko gudawa, tare da matsanancin ƙira. na jijiyoyin zuciya ko jijiyoyin bugun zuciya, tare da farfadowa da farfadowa (musamman idan ba a dauki hoton marasa lafiya ba), tare da gazawar koda, tare da gazawar hanta (duba sashe na "Dokar Musamman" Ania ")

Tsarin saki, abun da aka shirya da marufi

Akwai shi ta hanyar bayyananniyar mafita don allura a cikin nau'in sirinji 1.5 ml a girma (har zuwa 5 inji mai kwakwalwa. A cikin kwali na kwali).

1 ml na miyagun ƙwayoyi ya ƙunshi:

• 300 Abubuwa na insulin glargine,
• metacresol
• zinc chloride
• 85% glycerin,
• sodium hydroxide
• hydrochloric acid,
• ruwa don yin allura.

Aikin magunguna

Insulin aiki na dindindin wanda yake daidaita metabolism. Lokacin da aka cinye shi, nama yana motsawa don shan glucose, hana shi a cikin hanta da rage yawan taro. Bugu da ƙari, an inganta ƙwayar furotin.

Glargin yana aiki daidai da insulin na mutum. Lokacin fallasawa daga awanni 24 zuwa 36 - ya dogara da kasancewar motsa jiki da sauran dalilai masu alaƙa. Commonlyarancin da aka saba dashi, yana haifar da ƙwancin ƙwayar cuta idan aka kwatanta da takwarorinsu, ciki har da dare. Kusan babu wani tasiri ga canje-canje a cikin nauyin jiki, amma yana buƙatar abinci mai dacewa.

Pharmacokinetics

Bayan gudanar da aikin ƙarƙashin ƙasa, ɗaukar ciki yayi jinkiri, yana da tsawo, kuma yaɗuwa ko'ina cikin jiki. Halin daidaituwa shine kwana 3-4 bayan amfanin yau da kullun.

Wannan nau'in insulin yana haɗuwa da sauri a cikin jiki: rabin-rayuwar 18-18 awanni.

Babu wani sakamako na tsufa da jinsi game da tasiri na glargine, amma ya kamata a bayar da kashi na farko ga tsofaffi ƙara ƙasa da haɓakawa a hankali kuma daidai.

Nau'in 1 da nau'in ciwon sukari na 2 a cikin manya.

Umarnin don amfani (sashi)

An wajabta shi daban-daban daga likitan halartar. Ya dogara da buƙatar jikin mutum na glucose. An yanke shawarar tambayar kashi don dogara akan bayanan bincike na haƙuri. Ana yin allura sau ɗaya a lokaci guda na rana.

MUHIMMIYA! Abubuwan da ake amfani da su kawai an yarda da su.

Idan magani ya tsallake, to a cikin kowane hali ba za ku iya rama wannan tare da kashi biyu ba! Kuna buƙatar kawai bincika jini don maida hankali kan sukari kuma ku koma cikin tsarin da aka saba tare da saka idanu akan yanayin.

Tare da nau'in ciwon sukari na 1, ana amfani dashi a cikin haɗin kai tare da insulin aiki mai sauri don rufe buƙatarta tare da abinci.

Tare da nau'in ciwon sukari na 2, an haɗo shi da sauran magungunan hypoglycemic.

Maganin yakamata ya kasance a zazzabi a daki, wurin allurar - ciki, kwatangwalo da kafadu. Ya kamata a canza wurin allurar koyaushe don kawar da haɗarin lipodystrophy.

Side effects

1. Hypoglycemia.
2. Lipodystrophy.
3. Allergic halayen.
4. Ayyuka a wuraren allurar (itching, redness, bugu).
5. Retinopathy
6. Kurajewa.
7. Myalgia.
8. Rashin narkewa.

Kwayar cutar tana warke ta hanyar daidaitawa ko cire magani.

Yawan abin sama da ya kamata

Idan kashi yayi yawa, hypoglycemia na iya haɓaka. Alamun ta sune rauni, tashin zuciya da amai, rashin nutsuwa, har zuwa asarar sani da haɓaka.

Ana samun kwanciyar hankali mai narkewa ta hanyar cin abinci mai-carbohydrate. Ana kawar da matsakaici da mai tsanani ta hanyar allura ta glucagon ko bayani mai faɗi, daga asibiti. A kowane hali, ana buƙatar daidaita sashin insulin.

Hulɗa da ƙwayoyi

Yana nufin inganta aikin insulin glargine:

• na baki hypoglycemic jamiái
• ACE hanawa da MAO,
• rashin biyayya
• zaren wuta
• mai kyalli
• skwarin
• wakili
• salicylates,
• maganin rigakafin sulfonamide.

Magunguna waɗanda ke rage tasirin sa:

• glucocorticosteroids,
• danazol
• diazoxide
• kamuwa da cuta
• glucagon,
• isoniazid
• estrogens da progestogens,
• sabbin kayan tarihin,
• somatropin,
• tausayawa
• hodar iblis,
• magungunan gargajiya,
• masu hana masu kariya.

Abubuwan da zasu ba da sakamako iri-iri yayin da aka hada su:

Magungunan da ke rufe alamun rashin ƙarfi na hypoglycemia:

• beta hanawa,
• clonidine
• guanethidine,
• madarar ruwa.

Umarni na musamman

Tare da taka tsantsan:

• masu juna biyu da masu shayarwa
• mazan
• tare da hanta da koda,
• fama da cututtukan endocrine da jijiyoyin jijiyoyin zuciya ko tasoshin kwakwalwa,
• marasa lafiya tare da retinopathy.

Bai dace da kula da cutar ketoacidosis mai ƙazantawa da kawarwa daga cutar rashin haihuwa ba.

Marasa lafiya waɗanda ke buƙatar karancin insulin suma ba koyaushe dace ba. Ana bukatar gyaran gyale.

Lokacin tuki motocin, ya kamata a kula, tunda akwai haɗarin hauhawar jini. Zai fi kyau a ƙin tuƙi mota a yayin dukkan jiyya.

Ana fitar dashi ne kawai ta takardar sayan magani.

Kwatanta tare da analogues

Tujeo Solostar ya bambanta da sauran shirye-shiryen insulin a cikin kayanta. Bambanci tare da analogues ana amfani da su ana nuna su a tebur.

Suna, abu mai aiki	Mai masana'anta	Abvantbuwan amfãni da rashin amfani	Farashin, rub.
Lantus, glargine insulin	Sanofi-Aventis, Jamus	Ribobi: za a iya ba da umarnin ga yara daga shekara shida. Cons: ƙananan taro na abu mai aiki, sakamakon yana ƙare da sauri.	Alamar sirinji 3700/5 na 3 ml
Levemir, insulin detemir	Novo Nordisk, Denmark.	Ribobi: sun dace don amfani da mata masu juna biyu da yara daga shekaru 6, amma tare da madaidaitan daidaitawa. Fursunoni: inganci ba fãce fiye da a rana.	Daga allunan sirinji 2800/5 na 3 ml
Tresiba, degludec	Novo Nordisk, Denmark.	Ribobi: na aiki har zuwa awanni 42. Yana yiwuwa yara daga shekara guda. Cons: tsada mai tsada, ba koyaushe a cikin kantin magani ba.	Daga 7600

Duk wani amfani da wani nau'in insulin ya kamata ya kasance ƙarƙashin kulawar likitancin endocrinologist. An haramta shan magunguna kai tsaye!

Gabaɗaya, ana amfani da wannan kayan aiki ta hanyar kyakkyawan ra'ayi daga masu ciwon sukari tare da gwaninta, musamman idan aka kwatanta da sauran kwayoyi.

Olga: “Tun ina ɗan shekara 19 na kamu da ciwon sukari, na gwada magunguna daban-daban. A baya can, Lantus na wuƙa, amma sun daina ba shi bisa fa'idodi. An canza shi zuwa Tujeo. Ba zan iya samun amfani da shi ba tukuna, amma likita ya ba ku shawara ku bi rage cin abincin carb. Ina fatan komai zai yi kyau. Daga cikin ƙari, na lura cewa dogon tasiri yana da sauƙin. ”

Victor: “insulin“ Tujeo ”ya fi maida hankali fiye da“ Lantus ”, don haka na saba da shi na dogon lokaci. Amma gaba ɗaya, Ina son barga mai sukari, ba tare da saukad da su ba. Na bi abincin da na ba ku shawara kuma in ba ku shawara, to tabbas babu matsala. ”

Anastasia: “Ina son Tujeo fiye da Levemir, wanda kusan nake kusan shekara ɗaya. Har yanzu yana riƙe da sukari wanda ta kwana - da wannan na tashi. Babu hare-hare da daddare a cikin dare. Kuma mafi mahimmanci - yana da matukar dacewa don amfani, kuma an ba da shi don fa'idodi a kantin magani. ”

Anna: “Na kasance ina amfani da Lantus. Lokaci na ƙarshe da suka ba Tujeo a kantin magani, bayan sun nemi likita, sai ta yanke shawarar gwada shi. Na ɗan ƙara ɗan kashi na farko, da kuma kashi na Humalog, wanda nake amfani da shi. Bayan kwana uku na gwaji, an samo sashi mai dacewa, yanzu na bi shi. Ina son insulin na al'ada, babu korafi. ”

Dmitry: “Ina ɗan shekara 23, in yi amfani da allurar Lantus. Likita ya canza zuwa Tujeo na dan lokaci, kuma ban son shi. Sugar ya fara tsalle sosai, Dole ne in yi amfani da Novorapid. Bayan wata ɗaya na azaba, sai ya koma Lantus. Wannan magani bai dace da ni ba ko kaɗan. ”

Kammalawa

Kamar yadda kake gani, Tujeo Solostar yana da wadata da dama. Tare da zaɓin da ya dace na miyagun ƙwayoyi da kuma yadda yake amfani da shi, rayuwar mai ciwon sukari ta zama mafi kwanciyar hankali. Sabili da haka, ƙwararru suna ƙyamar insulins na dogon lokaci suna ɗaukar su. Kuma sake dubawa game da wannan magani ya nuna cewa ya dace sosai ga yawancin marasa lafiya da masu ciwon sukari.

Sashi da gudanarwa

Janar shawarwari
Rukunin Tujeo SoloStar® (insulin glargine 300 IU / ml) suna nuni ne kawai ga Tujeo SoloStar® kuma basu dace da sauran raka'a waɗanda ke nuna ƙarfin aikin sauran analogues na insulin ba. Ya kamata a gudanar da Tugeo SoloStar® a ƙarƙashin sau ɗaya a rana a kowane lokaci na rana, zai fi dacewa a lokaci guda. Magungunan Tujeo SoloStar® tare da allura guda ɗaya yayin rana yana ba ku damar samun jituwa mai sauƙin don allura: idan ya cancanta, marasa lafiya na iya yin allura a cikin awanni 3 kafin ko awanni 3 bayan lokacinsu na yau da kullun.
Ya kamata a ƙaddara darajar daidaita yawan glucose na jini, kashi da lokacin gudanarwa / gudanar da magunguna na hypoglycemic kuma daidaita su daban-daban.
Hakanan ana iya buƙatar daidaita yanayin ƙirar, alal misali, ta canza nauyin mara haƙuri, salon rayuwa, canza lokacin gudanarwar insulin, ko a wasu yanayi waɗanda zasu iya ƙara haɓakar tsinkayar zuwa haɓakar hypo- ko hyperglycemia (duba sashin "Umarni na Musamman"). Duk wani canje-canje a cikin adadin insulin ya kamata a aiwatar dashi tare da taka tsantsan kuma a ƙarƙashin kulawar likita kawai.
Tujeo SoloStar® ba insulin zaɓi bane don maganin ketoacidosis mai ciwon sukari. A wannan halin, ya kamata a zaɓi fifiko don gudanar da aikin insulin na ɗan gajeren lokaci.
A cikin duk marasa lafiya da ke dauke da ciwon sukari, ana bada shawara don saka idanu akan yawan glucose a cikin jini.
Farkon amfani da miyagun ƙwayoyi Tujo SoloStar
Nau'in Marasa lafiya na 1
Tujeo SoloStar® yakamata a yi amfani da shi sau ɗaya a rana a hade tare da insulin, ana gudanar dashi yayin abinci, kuma yana buƙatar gyara mutum gwargwado
Nau'in marassa lafiya na guda 2
Shafin farko da aka ba da shawarar shine 0.2 U / kg na nauyin jiki sau ɗaya a rana, tare da daidaituwa na kowane mutum.
Sauyawa daga gudanarwar insulin glargine 100 IU / ml zuwa miyagun ƙwayoyi Tujeo SoloStar® kuma, yana magana, daga miyagun ƙwayoyi Tujeo SoloStar® zuwa insulin glargin 100 IU / ml.
Insulin glargine 100 IU / ml da Tujeo SoloStar® ba su dace ba a cikin magungunan likitancin su, halayen magunguna da tasirin asibiti. Dangane da wannan, canjin daga insulin glargine 100 PIECES / ml zuwa miyagun ƙwayoyi Tujo SoloStar® kuma mataimakin yana buƙatar kulawa da likita, kulawa da hankali na rayuwa da daidaita daidaituwa na kwayoyi:

• Sauya daga insulin glargine 100 IU / ml zuwa Tujeo SoloStar® ana iya yin kowane guda ɗaya, amma ana buƙatar ƙarin kashi na Tujeo SoloStar® don cimma maƙasudin maƙasudin yawan ƙwayar ƙwayar plasma.
• Lokacin juyawa daga amfani da miyagun ƙwayoyi Tujo SoloStar® zuwa insulin glargine 100 IU / ml don rage haɗarin hypoglycemia, ya kamata a rage kashi (kusan 20%), biye da sauye sauye idan ya cancanta

Ana ba da shawarar saka idanu sosai a cikin lokacin da a cikin fewan makonni na farko bayan sauyawa daga ɗayan waɗannan magungunan zuwa wani.
Sauyawa daga wasu insulin na basal zuwa Tujeo SoloStar®

Lokacin canzawa daga tsarin kulawa tare da matsakaiciyar matsakaiciya da na dogon lokaci zuwa insimen magani tare da Tujeo SoloStar®, yana iya zama dole a canza sashin insulin basal da daidaita yanayin motsa jiki na lokaci guda (canza allurai da lokacin gudanarda insulins na gajeran lokaci ko insulin insulin insalins, ko allurai marasa insulin hypog) kwayoyi).

• Canjin daga allura guda daya na insulin basal yayin rana zuwa guda na gudanarwar Tujeo SoloStar® yayin rana ana iya aiwatar da su bisa asalin kashi ɗaya daga kashi ɗaya cikin kashi na insulin na asali.
• Lokacin canzawa daga sau biyu a kullum na insulin insulin zuwa guda biyu na Tujeo SoloStar®, shawarar farko na Tujeo SoloStar® shine kashi 80% na yawan insulin na yau da kullun, maganin da yake dainawa.

Marasa lafiya tare da yawan allurai na insulin, saboda kasancewar rigakafi ga insulin na mutum, na iya samun ingantacciyar amsa ga Tujo SoloStar®.
Yayin canzawa zuwa ƙwayar Tujo SoloStar® kuma a cikin weeksan makonni bayan shi, ana bada shawarar saka idanu akan metabolic.
Tare da ingantacciyar iko na rayuwa da kuma sakamakon haɓaka cikin ƙwayar insulin, ana buƙatar ƙarin daidaita sashi. Hakanan ana iya buƙatar gyaran allurar dosing, alal misali, lokacin da ake canza nauyin jikin mutum ko salon rayuwar mai haƙuri, lokacin da lokacin kulawa da kashi na insulin ya canza, ko kuma lokacin da wasu yanayi suka haifar da haɓaka yanayin haɓakar hauhawar jini da hauhawar jini.
Sauyawa daga gabatarwar miyagun ƙwayoyi Tujo SoloStar® zuwa wasu abubuwan insulins

Yayin sauye-sauye daga mulkin Tujo SoloStar the zuwa amfani da sauran insulin basal kuma a cikin 'yan makonni bayan shi, ana ba da shawarar kulawa da likita da kulawa da kulawa na rayuwa.
Ana bada shawara ga koma zuwa umarnin don amfani da miyagun ƙwayoyi wanda aka koma da mara lafiya.
Hadawa da kiwo
Tujeo SoloStar® kada a haɗa shi da sauran insulin. Hadawa yana haifar da canji a cikin bayanin ayyukan Tujeo SoloStar® na tsawon lokaci kuma yana haifar da hazo.
Tujeo SoloStar® bai kamata a tsarma ba. Dilution na iya haifar da canji a bayanin martabar aikin miyagun ƙwayoyi Tujo SoloStar® lokaci.
Groupsungiyoyin haƙuri na musamman
Yara
Tsaro da inganci na Tujeo SoloStar® a cikin yara da matasa masu shekaru 18 ba a kafa su ba tukuna (duba sashen Pharmacokinetics).
Tsofaffi marasa lafiya
Ana iya amfani da Tujeo SoloStar® a cikin tsofaffi marasa lafiya. Ana ba da shawarar kulawa da hankali sosai akan yawan glucose na jini, kuma ya kamata a zaɓi sashin insulin ɗin daban-daban. A cikin marasa lafiya tsofaffi, ci gaban ci gaba a cikin aiki na renal na iya haifar da raguwa na dindindin a cikin buƙatar insulin (duba sassan "Magunguna", "Magunguna kan magunguna" da "Umarnin na Musamman").
Marasa lafiya tare da gazawar koda
Ana iya amfani da Tujeo SoloStar® a cikin marasa lafiya da gazawar renal. Ana ba da shawarar kulawa da hankali sosai akan yawan glucose na jini, kuma ya kamata a zaɓi sashin insulin ɗin daban-daban. A cikin marasa lafiya da ƙarancin na koda, buƙatar insulin na iya raguwa saboda raguwar yanayin metabolism (duba sassan "Umarnin na Musamman", "Pharmacodynamics" da "Pharmacokinetics").
Marasa lafiya tare da raunin hanta
Ana iya amfani da Tujeo SoloStar® a cikin marasa lafiya da gazawar hanta. Ana ba da shawarar kulawa da hankali sosai akan yawan glucose na jini, kuma ya kamata a zaɓi sashin insulin ɗin daban-daban. A cikin marasa lafiya da rashin isasshen hepatic, buƙatar insulin na iya raguwa saboda raguwar gluconeogenesis da raguwa a cikin metabolism (duba sassan "Magunguna Pharmacodynamics". "Pharmacokinetics" da "Umarnin na Musamman").
Hanyar aikace-aikace
Tujeo SoloStar® yana allura cikin ƙashin ciki mai ciki, kafada ko kwatangwalo. Wuraren allurar ya kamata ya canza tare da kowane sabon allura a cikin wuraren da aka ba da shawarar don gudanar da magani.
Tujeo SoloStar® ba'a yi niyya don gudanarwa ba.
Tsawan aikin insulin glargine ana lura dashi ne kawai lokacin da aka gabatar dashi cikin kitse na subcutaneous. Gudun cikin jijiya na kashi biyu na subcutaneous kashi na iya haifar da mummunan hypoglycemia.Tujeo SoloStar® ba'a yi nufin amfani dashi tare da famfon jiko na insulin ba.
Tujeo SoloStar® bayani ne bayyananne, ba dakatarwa ba ne, don haka sake tayar da zaune tsaye kafin amfani ba ya bukatar.
Yin amfani da alƙawarin Tujeo SoloStar® sirinji, ana iya gudanar da allurai na 1 zuwa 80 a allura a cikin adadin kashi 1.

• Tujeo SoloStar® Syringe Pen Dose Counter yana nuna adadin raka'a na Tujeo SoloStar® da za'a gudanar dashi. Tujeo SoloStar® Syringe Pen an inganta shi musamman don shirye-shiryen Tujeo SoloStar®, don haka ba a buƙatar ƙarin juyawa na kashi.
• Tujeo SoloStar® bai kamata a cire shi daga cikin maɓallin siket ɗin cikin sirinji (duba “Umarnin na Musamman”).
• Kar a sake amfani da allura. Kafin kowane allura, ya kamata a haɗa sabon allurar da za ta iya kasancewa a ciki. Yin amfani da allura yana kara hadarin clogging, wanda kan iya haifar da karancin kashi ko yawan shan ruwa. Bayan haka, yin amfani da sabon allurar bakararre ga kowane allura yana rage hadarin kamuwa da kamuwa da cuta.
• Idan allurar ta toshe, mai haƙuri dole ne ya bi umarnin a cikin Mataki na 3 “Umarnin don Amfani da Tujeo SoloStar® Syringe Pen” (duba ƙasa).

Don hana yiwuwar watsa cututtukan jini, ba za a yi amfani da alkalami na insulin fiye da ɗaya mai haƙuri ba, koda kuwa an maye gurbin allura.
Don amfani da Tujeo SoloStar® Syringe Pen da kyau, duba ƙasa "Umarnin don Amfani da Tujeo SoloStar® Syringe Pen". Don ware yiwuwar kuskuren aiki (mai haɗari) na wani nau'in insulin maimakon Tujeo SoloStar®, koyaushe bincika lakabin akan alƙalin syringe a gaban kowane allurar (a kan alamar sigar ta Tujeo SoloStar® alkalami, maida hankali "300 IU / ml" ana nuna shi akan bango mai launi) .
Kalmar yin amfani da miyagun ƙwayoyi a cikin Tujeo SoloStar pen yardar sirinji ta zubar bayan amfani na farko shine makonni 4 lokacin da aka adana shi cikin duhu. An bada shawara don nuna ranar da aka fara amfani da shi akan alamar alkalami na alkairin.